Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of anlotinib combination therapy in previously treated HER2-negative advanced breast cancer
ChiCTR2400081835Phase 4Completed
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in breast cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started Mar 2024; status: completed.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400081835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081835.